Avoiding Neuromuscular Blockers to Reduce Complications | MicrobiomeTrials← Back to trialsNCT03962725
Avoiding Neuromuscular Blockers to Reduce Complications
TERMINATEDPHASE4INTERVENTIONAL
Trial Details
Start: 2019-08-07Est. Completion: 2022-12-19
Enrollment target: 3 participants Locations- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
MelanomaLi-Fraumeni SyndromePulmonary BlastomaChordomaCongenital Bone Marrow Failure SyndromesCostello SyndromeFanconi AnemiaCFC Syndrome (CFCS)Legius SyndromeRASopathies
Background:
Clinical Genetics Branch (CGB) researchers study individuals and populations at high genetic risk of cancer…
Rockville, United StatesEst. completion Jan 1, 2035
SARS-CoV-2Influenza, HumanRespiratory Syncytial Virus InfectionsRespiratory Distress SyndromeSystemic Inflammatory Response Syndrome
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B)…
Alcalá de Henares, SpainEst. completion Oct 2, 2026
Patient-Ventilator InteractionAsynchrony, Patient-Ventilator
Patient-ventilator interaction describes how a mechanically ventilated patient's breathing effort aligns with ventilator…
Al Ahmadi, KuwaitCompleted Mar 1, 2027